COMPASS Pathways Plc American Depository Shares (CMPS) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 73.8% versus a gain of 1.3%. Zenas BioPharma is the larger company by market cap ($1.78 billion vs $1.66 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | ZBIO |
|---|---|---|
| Share price | $12.00 | $27.26 |
| Market cap | $1.66B | $1.78B |
| 1-day change | +4.62% | +3.89% |
| YTD return | +66.23% | -27.73% |
| 1-year return | +73.79% | +1.31% |
| 5-year return | -64.40% | — |
| EPS (TTM) | $-3.76 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.00M |
| Revenue growth (YoY) | — | +100.00% |
| Net income (latest FY) | $-287.86M | $-377.74M |
| Operating margin | — | -3830.57% |
| Net margin | — | -3777.37% |
| 52-week high | $15.87 | $44.60 |
| 52-week low | $4.88 | $13.50 |
| Distance from 52-week high | -24.39% | -38.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +97.92% | +75.64% |
| Average volume | 3.03M | 733.34K |
| Shares outstanding | 138.48M | 65.18M |
| Employees | 156 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed ZBIO by 72.5 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
CMPS vs ZBIO FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.78B compared with $1.66B for COMPASS Pathways Plc American Depository Shares (CMPS).
Which stock has performed better over the past year, CMPS or ZBIO?
CMPS returned +73.79% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.